| Co-Chairs |
|
Roy S. Herbst, MD, PhD
Professor of Medicine
Chief, Section of Thoracic Medical Oncology
Department of Thoracic/Head & Neck
Medical Oncology
Barnhart Family Distinguished Professor
in Targeted Therapies
The University of Texas
M. D. Anderson Cancer Center
Houston, TX
|
|
Rafael Rosell, MD, PhD
Chief, Medical Oncology Service
Scientific Director of Oncology Research
Catalan Institute of Oncology
Hospital Germans Trias I Pujol
Barcelona, Spain
|
| |
| |
|
| |
CME-Accredited Webcasts, Presentation and Audio Downloads, and i-Tunes Podcast Downloads
4 presentations and 4 Q&A sessions from the live course
Emerging Novel Strategies for Personalized Initial and Maintenance Therapy of NSCLC: Critical Questions Addressed by the Experts
held in Chicago, IL on June 5, 2010
|
You may participate in any or all of the sessions for CME credit or a Certificate of Attendance after you review the required ACCME (Accreditation Council on Continuing Medical Education) information on this page.
|
|
Menu
|
|
Overview of This CME-Accredited Educational Activity
Your Options for Methods of Participation are:
- View and/or listen to any of the sessions (listed below) via an Adobe Flash Webcast
- Download any slides as Adobe Acrobat files
- Download any audio only as MP3s or Podcasts
- Request a DVD-ROM of all sessions
|
Sessions can be individually reviewed for credit. You can participate in as few or as many as you desire.
CME-Accredited Educational Activity Dates and Time to Complete
Date of release: September 20, 2010
Date expires (CME credit will not be avaliable): September 20, 2011
Average time to complete each individual session: 20 minutes
Time to complete entire activity: 2 hours
Overview
This activity will use a faculty consisting of five scientific and clinical NSCLC experts from the USA and Europe to present, review, and discuss how to employ novel anti-EGFR and anti-angiogenic therapies into their treatment strategies for initial and maintenance therapy for this malignancy.
Following each presentation will be a 10-minute Interactive Roundtable Discussion during which the other expert faculty members provide their individual perspectives addressing the specific critical question. During the final Interactive Roundtable Discussion the audience may ask questions of the faculty.
Before the activity begins, a pre-activity educational assessment consisting of approximately eight patient care treatment-strategy questions with multiple-choice answers will be conducted to determine how you currently treat your patients in order to determine a baseline of current medical hematologists' practices.
Educational Needs Summary
During the past year clinical data has emerged resulting in practice-changing paradigm shifts for the treatment and management of patients with NSCLC. This is especially relevant for initial and maintenance therapy of NSCLC with novel strategies targeting EGFR and inhibiting angiogenesis. As a result, with these newer therapeutic options several critical questions need to be addressed to help physicians treat and manage their NSCLC patients with the optimal personalized strategies using targeted therapies.
The following is list of all sessions
|
Activity Agenda |
| 1. |
Will combining EGFR and angiogenesis inhibition for NSCLC maintenance therapy improve overall survival?
Vincent A. Miller, MD |
| 2. |
Interactive Roundtable Discussion
Faculty and Audience |
| 3. |
Will initial and maintenance therapy with oral EGFR inhibition become the new standard for EGFR mutation-positive NSCLC?
Rafael Rosell, MD , PhD |
| 4. |
Interactive Roundtable Discussion
Faculty and Audience |
| 5. |
Will initial and maintenance therapy with angiogenesis inhibition become a standard option for nonsquamous NSCLC?
Alan B. Sandler, MD |
| 6. |
Interactive Roundtable Discussion
Faculty and Audience |
| 7. |
Will angiogenesis inhibition become an essential therapy component with chemotherapy for initial and maintenance therapy for nonsquamous NSCLC?
Jyoti D. Patel, MD |
| 8. |
Interactive Roundtable Discussion
Faculty and Audience |
|
|
|
Educational Objectives
At the conclusion of all of these enduring materials, you should be able to:
- Devise strategies for optimally personalizing targeted therapies for nonsquamous NSCLC patients with advanced or metastatic disease.
- Compare and contrast the new scientific and clinical data regarding the various targeted therapy options for maintenance therapy for nonsquamous NSCLC and determine how to best utilize these strategies.
- Devise optimal initial therapy strategies for mutationpositive NSCLC patients.
- Determine how to best treat patients with nonsquamous NSCLC with combinations of angiogenesis and EGFR inhibition strategies.
Target Audience
This symposium is designed for medical oncologists, hematologist/oncologists, radiation oncologists, surgical oncologists, pathologists, nurse practitioners/nurses, pharmacists, fellows and other health care professionals who are involved in the treatment or management of patients with NSCLC. This malignancy is treated optimally by a multidisciplinary approach of clinicians and, thus, they are all targeted for invitation to this symposium.
CME Accreditation & Credit Designation
The Oncology Learning Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Oncology Learning Center designates this educational activity for a maximum of 2 AMA PRA Category 1
Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME Certificate or Certificate of Participation
The relevant section(s) of the Evaluation Form pertaining to the session(s) of the enduring materials you have viewed or listened to, and the Request for Credit Form must be completed and submitted to the Oncology Learning Center following your participation in the enduring material educational activity to obtain CME credit. Physicians and other participants will be able to print their certificates after they complete these Forms.
Disclosure of Conflicts of Interest
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by the Oncology Learning Center must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an OLC-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. |
|
Faculty Disclosures
It is the policy of the Oncology Learning Center, Inc. (OLC) to ensure that all of its educational activities and materials are of the highest quality, and are balanced, objective, independent, free of commercial bias, and planned and developed with scientific rigor with strict adherence to all Accreditation Council for Continuing Medical Education (ACCME) rules and policies. The OLC evaluates all content, faculty and faculty disclosures for any potential conflicts of interest. Should any conflicts of interest be identified these conflicts are resolved in advance of the educational activity by independent peer reviewers who are experts in the subjects of the educational activity.
All faculty and OLC staff participating in the content, planning or implementation of an educational CME activity are required to disclose to the audience of the educational activity any relevant financial relationships or interests and to assist in the resolution of any conflict of interest that may arise from the relationship(s) or interest(s). It is also the policy of the OLC to require all faculty presenters to make a meaningful disclosure to the audience of their discussions of unlabeled or FDA unapproved drugs, products, tests or devices. This information will be available as part of the educational activity and related material.
The following faculty and OLC staff have reported real or potential relevant conflicts of interest and these conflicts have been resolved, prior to this educational activity through a peer-review process by two medical oncologists who have had no affiliation with this educational activity other than the peer review process. This is documented on this page immediately following the financial disclosures below.
|
Roy S. Herbst, MD, PhD
I have no real or apparent conflicts of interest to report.
Rafael Rosell, MD, PhD
I have no real or apparent conflicts of interest to report.
Vincent A. Miller, MD
Consultant: Roche, Genentech, Sanofi-Aventis, Boehringer Ingelheim
Contracted Research: BMS, Pfizer
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
Jyoti D. Patel, MD
I have no real or apparent conflicts of interest to report.
Alan B. Sandler, MD
Consultant: Abraxis, Boehringer-Ingelheim, Eli Lilly, Genentech, Glaxo Smith Kline, Novartis, Pfizer, Roche, VeriStrat
Grants/Research Support: BMS, Eli Lilly, Genentech, OSI, Pfizer, Roche
Speakers' Fees: Eli Lilly, Genentech
Honoraria: Amgen, BMS, Daiichi-Sankyo, Eli Lilly, Genentech, Glaxo Smith Kline
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
OLC Staff
We have no real or apparent conflicts of interest to report. |
Faculty Affiliations
Roy S. Herbst, MD, PhD (Co-Chair)
Professor of Medicine
Chief, Section of Thoracic Medical Oncology
Department of Thoracic/Head & Neck
Medical Oncology
Barnhart Family Distinguished Professor
in Targeted Therapies
The University of Texas
M. D. Anderson Cancer Center
Houston, TX
|
|
Rafael Rosell, MD, PhD (Co-Chair)
Chief, Medical Oncology Service
Scientific Director of Oncology Research
Catalan Institute of Oncology
Hospital Germans Trias I Pujol
Barcelona, Spain
|
Vincent A. Miller, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, NY
|
|
Alan B. Sandler, MD
Professor of Medicine
Division Chief, Hematology & Medical Oncology
DeArmond Chair, Clinical Cancer Research
Oregon Health & Science University
Portland, OR
|
Jyoti D. Patel, MD
Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Chicago, IL
|
|
|
|
Peer Review Process of Conflicts of Interest
This educational activity has been independently peer-reviewed.
Disclosure of Unlabeled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians' Desk Reference.
The Oncology Learning Center (OLC) does not recommend the use of any agent outside of the FDA labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the OLC. Please refer to the official FDA prescribing information for each product for discussion of approved indicated, contraindications, and warnings.
Acknowledgement of Supporters
| Educational Grants |
Sincere appreciation is extended to the following companies for their generous support of this educational meeting: |
 |
|
